MAMDC2

Across TCGA pan-cancer cohorts, MAMDC2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MAMDC2 data layer compared with 28 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher MAMDC2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated MAMDC2 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

LUAD, LSCC, and HNSC are the cancer types where MAMDC2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Quartile	All	0.816	1.000	.003	12	view →
LSCC	OS	Median	II,III,IV	0.901	1.000	.017	7	view →
HNSC	OS	Median	II,III,IV	0.631	0.801	.015	6	view →
PDAC	DFS	Quartile	All	0.816	0.678	.038	2	view →
CCRCC	OS	Tertile	All	1.000	0.723	.045	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MAMDC2–LUAD (DFS)

Open the LUAD breakdown →